| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $226,500 | 1 | 3 |
Sells | $63,253,727 | 29 | 97 |
| Davidson Michael H. | Chief Executive Officer | 1 | $226,500 | 5 | $25.33M | $-25.1M |
| Smither John W | director | 0 | $0 | 1 | $40,512 | $-40,512 |
| LANGE LOUIS G | director | 0 | $0 | 2 | $2.19M | $-2.19M |
| Somaiya Mayur Ian | Chief Financial Officer | 0 | $0 | 3 | $3.43M | $-3.43M |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 0 | $0 | 7 | $15.52M | $-15.52M |
| Kooij Louise Frederika | Chief Accounting Officer | 0 | $0 | 11 | $16.75M | $-16.75M |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is …
Over the last 12 months, insiders at NewAmsterdam Pharma Company N.V. have bought $226,500 and sold $63.25M worth of NewAmsterdam Pharma Company N.V. stock.
On average, over the past 5 years, insiders at NewAmsterdam Pharma Company N.V. have bought $364,235 and sold $42.41M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Davidson Michael H. (Chief Executive Officer) — $226,500.
The last purchase of 10,000 shares for transaction amount of $226,500 was made by Davidson Michael H. (Chief Executive Officer) on 2026‑09‑14.
| 2026-09-30 | Sale | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 50,246 0.0442% | $25.03 | $1.26M | -14.00% | |
| 2026-09-14 | Davidson Michael H. | Chief Executive Officer | 10,000 0.0082% | $22.65 | $226,500 | -3.87% | ||
| 2026-09-04 | Sale | Smither John W | director | 1,600 0.0013% | $25.32 | $40,512 | -15.04% | |
| 2026-08-24 | Sale | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 125,000 0.1015% | $26.91 | $3.36M | -16.89% | |
| 2026-07-20 | Sale | Kooij Louise Frederika | Chief Accounting Officer | 105,000 0.0918% | $30.34 | $3.19M | -19.75% | |
| 2026-06-22 | Sale | Kooij Louise Frederika | Chief Accounting Officer | 40,000 0.0335% | $30.20 | $1.21M | -14.71% | |
| 2026-05-26 | Sale | Kooij Louise Frederika | Chief Accounting Officer | 65,000 0.0543% | $35.69 | $2.32M | -23.97% | |
| 2026-03-11 | Sale | LANGE LOUIS G | director | 44,619 0.0377% | $30.42 | $1.36M | -5.09% | |
| 2026-03-09 | Sale | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 101,409 0.0895% | $30.29 | $3.07M | -3.14% | |
| 2026-03-06 | Sale | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 94,124 0.0831% | $30.32 | $2.85M | -0.13% | |
| 2026-03-06 | Sale | LANGE LOUIS G | director | 28,186 0.0241% | $29.41 | $828,950 | -0.13% | |
| 2026-03-05 | Sale | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 104,467 0.0914% | $30.30 | $3.17M | -1.05% | |
| 2026-03-02 | Sale | Davidson Michael H. | Chief Executive Officer | 443,707 0.3619% | $33.25 | $14.75M | -9.08% | |
| 2026-02-26 | Sale | Davidson Michael H. | Chief Executive Officer | 183,332 0.1568% | $33.71 | $6.18M | -12.89% | |
| 2026-02-25 | Sale | Davidson Michael H. | Chief Executive Officer | 58,253 0.0511% | $35.30 | $2.06M | -14.71% | |
| 2026-02-24 | Sale | Davidson Michael H. | Chief Executive Officer | 64,708 0.0565% | $36.15 | $2.34M | -17.08% | |
| 2026-02-20 | Sale | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 45,481 0.0398% | $35.31 | $1.61M | -15.74% | |
| 2026-01-28 | Sale | Kooij Louise Frederika | Chief Accounting Officer | 32,612 0.028% | $31.80 | $1.04M | -4.71% | |
| 2026-01-27 | Sale | Kooij Louise Frederika | Chief Accounting Officer | 39,816 0.0351% | $32.62 | $1.3M | -6.86% | |
| 2026-01-26 | Sale | Kooij Louise Frederika | Chief Accounting Officer | 34,400 0.0307% | $32.78 | $1.13M | -6.09% |
| Davidson Michael H. | Chief Executive Officer | 792923 0.6783% | $15.78M | 3 | 6 | +16.5% |
| LANGE LOUIS G | director | 10360 0.0089% | $206,164.00 | 1 | 2 | <0.0001% |
| Topper James N | director | 3028524 2.5906% | $60.27M | 9 | 0 | +37.36% |
| Audet Juliette Berangere | Chief Business Officer | 1104 0.0009% | $21,969.60 | 1 | 0 | +32.82% |
$21,345,882 | 83 | 94.45% | $2.19B | |
$52,263,649 | 70 | 1.18% | $2.49B | |
$108,353,116 | 49 | 15.41% | $2.17B | |
$586,486,795 | 47 | 4.28% | $2.38B | |
$154,047,855 | 36 | 79.21% | $2.21B |
| Increased Positions | 114 | +78.62% | 13M | +10.46% |
| Decreased Positions | 62 | -42.76% | 14M | -11.92% |
| New Positions | 62 | New | 5M | New |
| Sold Out Positions | 11 | Sold Out | 1M | Sold Out |
| Total Postitions | 197 | +35.86% | 119M | -1.46% |
| Frazier Life Sciences Management, L.P. | $587,909.00 | 14.78% | 16.7M | +94,882 | +0.57% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $377,313.00 | 9.49% | 10.72M | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $356,891.00 | 8.97% | 10.14M | 0 | 0% | 2025-09-30 |
| Capital World Investors | $345,759.00 | 8.69% | 9.82M | +1M | +17.11% | 2025-09-30 |
| Fcpm Iii Services B.V. | $324,276.00 | 8.15% | 9.21M | -1M | -13.35% | 2025-09-30 |
| Viking Global Investors Lp | $227,939.00 | 5.73% | 6.48M | -503,000 | -7.21% | 2025-09-30 |
| Fmr Llc | $194,842.00 | 4.9% | 5.54M | +4M | +190.63% | 2025-09-30 |
| Deerfield Management Company, L.P. | $150,188.00 | 3.78% | 4.27M | -849,260 | -16.6% | 2025-09-30 |
| Jennison Associates Llc | $147,789.00 | 3.72% | 4.2M | +1M | +42.51% | 2025-09-30 |
| Wellington Management Group Llp | $141,508.00 | 3.56% | 4.02M | +697,129 | +20.98% | 2025-09-30 |